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http://www.biomedcentral.com/1471-2393/14/322RESEARCH ARTICLE Open AccessMedication exposure during pregnancy: a pilot
pharmacovigilance system using health and
demographic surveillance platform
Dominic Mosha1,2*, Festo Mazuguni1, Sigilbert Mrema1, Salim Abdulla1 and Blaise Genton2,3Abstract
Background: There is limited safety information on most drugs used during pregnancy. This is especially true for
medication against tropical diseases because pharmacovigilance systems are not much developed in these settings.
The aim of the present study was to demonstrate feasibility of using Health and Demographic Surveillance System
(HDSS) as a platform to monitor drug safety in pregnancy.
Methods: Pregnant women with gestational age below 20 weeks were recruited from Reproductive and Child
Health (RCH) clinics or from monthly house visits carried out for the HDSS. A structured questionnaire was used to
interview pregnant women. Participants were followed on monthly basis to record any new drug used as well as
pregnancy outcome.
Results: 1089 pregnant women were recruited; 994 (91.3%) completed the follow-up until delivery. 98% women
reported to have taken at least one medication during pregnancy, mainly those used in antenatal programmes.
Other most reported drugs were analgesics (24%), antibiotics (17%), and antimalarial (15%), excluding IPTp.
Artemether-lumefantrine (AL) was the most used antimalarial for treating illness by nearly 3/4 compared to other
groups of malaria drugs. Overall, antimalarial and antibiotic exposures in pregnancy were not significantly associated
with adverse pregnancy outcome. Iron and folic acid supplementation were associated with decreased risk of
miscarriage/stillbirth (OR 0.1; 0.08 – 0.3).
Conclusion: Almost all women were exposed to medication during pregnancy. Exposure to iron and folic acid had
a beneficial effect on pregnancy outcome. HDSS proved to be a useful platform to establish a reliable
pharmacovigilance system in resource-limited countries. Widening drug safety information is essential to facilitate
evidence based risk-benefit decision for treatment during pregnancy, a major challenge with newly marketed
medicines.
Keywords: Medication, Pregnancy, PharmacovigilanceBackground
Access to different therapeutic drugs such as antibiotics,
antimalarial and antiretroviral (ARVs) have improved in re-
cent years in most African countries, including Tanzania,
thanks to the efforts facilitated by government, private sec-
tor and donor agencies [1,2]. Safety of some of these ther-
apies is unknown during pregnancy because pregnant
women are not involved in clinical trials during the drug* Correspondence: dfmosha@hotmail.com
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products come to market with little human data available
regarding safety in pregnancy. Studies from animal models
have been used to provide safety information during preg-
nancy at the time the new drug is approved. However, such
findings are not easily translated into human risk. In most
cases, information regarding safety of product or drug use
during pregnancy is collected post product approval [3,4].
Sufficient and valid data on safety of drug use during
pregnancy is of high public health importance so as to
facilitate evidence based risk-benefit decision among
health providers.Ltd. This is an Open Access article distributed under the terms of the Creative
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and US is reported to have increased in the past 10 years
[5,6]. In most developing countries, where proper drug
monitoring system during pregnancy does not exist, it is
difficult to know the magnitude of drug exposure in
pregnancy. There are few studies in sub-Saharan Africa
which have attempted to assess prevalence of drug use
in pregnancy and its relation to pregnancy outcome [7,8].
A study in Mozambique reported that antibiotics agents
were the most common drugs used (41%), followed by
antimalarial drugs (24%). Drug exposure in general was
associated with a two fold increase risk of stillbirth [8].
First trimester of pregnancy is the most harmful
period for teratogenic exposure because it is when or-
ganogenesis takes place albeit, some teratogens may have
effect in later stage of pregnancy and may even cause
miscarriage [9,10]. Common medicines such as tetracyc-
line, metronidazole, albendazole, mebendazole, efavirenz
(EFV), sulphadoxine-pyrimethamine (SP) and artemisinin-
based combination therapy (ACT) are some of therapeutic
drugs which are not recommended during first trimester
due to fear of embryo-toxicity [11,12]. All these reported
teratogenic drugs and many other which are known or
not yet confirmed to have deleterious effects on the foetus
are still used by women of childbearing age and pregnant
women to treat different illnesses [13,14]. Thus, there are
insufficient safety studies in pregnancy on most drugs
used for the treatment of tropical diseases [15].
Demographic Surveillance System (DSS) is an ideal
platform to establish pharmacovigilance system in preg-
nancy. People in DSS area are routinely being followed
to update their information in the database. It is there-
fore easy to identify early enough vital events such as
pregnancy, birth and death. A link between the DSS
members and health care at the nearby facility can be
established with facilitated follow-up of pregnant women.
The present study aimed at demonstrating the feasibility
of using Health and Demographic Surveillance System
(HDSS) as a platform level to monitor drug safety in
pregnancy.
Methods
Study site and HDSS platform
The study was conducted using the platform of the
Rufiji Health and Demographic Surveillance System
(HDSS) which is located in Coastal region, Eastern
Tanzania. The area has hot weather throughout the year
and two rainy seasons. Rufiji HDSS monitors a popula-
tion of about 97,000; they are all recorded in the data-
base including social and health characteristics. Data
from all 13 health facilities within DSS catchment area
are also routinely being collected. These health facilities
have Reproductive and Child Health (RCH) clinic ser-
vices. The prevalence of women delivering in healthfacilities in the study area is 74%. Fertility rate is 4.8
and the maternal mortality ratio is 70 per 100,000 live
births [16].
The prevalence of malaria parasitaemia is 14%, and
Plasmodium falciparum is the predominant species [17].
Malaria is the leading cause of mortality in the district
across all ages. It is followed by HIV disease, tubercu-
losis and pneumonia [18]. Details of the study area and
population have been described elsewhere [19].
Study design and population
Enrollment
This was an observational prospective study conducted
between April 2012 and March 2013. Pregnant women
with a gestational age below 20 weeks and residing in
the HDSS area were enrolled in the study and followed
until delivery. Participants were recruited from both
RCH clinics during their routine clinic visits and from
the community through monthly round-based house
visits. The set-up of HDSS facilitated early identification
of pregnancy status in women of childbearing age
through routine HDSS quarterly surveys. A rapid urine
pregnancy test was performed for women who were not
sure of their pregnancy status.
Follow up and pregnant outcome ascertainment
All enrolled participants were followed up on a monthly
basis until delivery. Nurses and field workers were re-
sponsible for follow-ups in the RCH clinic and community,
respectively. Participants were given a unique identification
number which was attached to their RCH card and patient’s
medical log. These procedures allowed to easily identifying
study participants. During enrolment and follow-ups, par-
ticipants were always encouraged to attend monthly RCH
clinic visits and to deliver in the health facility. Women
were closely followed at home within two weeks of the ex-
pected date of delivery, especially for participant with miss-
ing information from the health facility. This allowed to
knowing whether the participant had already delivered or
not. Even for women delivering at home, they were always
encouraged to report to the RCH clinic afterwards. No in-
centive was given to participants while attending RCH
clinic or delivering in the health facility.
A structured questionnaire was used to interview for
socio-demographic information, obstetrics and medical
history. Physical examination, blood screening test for
HIV, syphilis and haemoglobin were performed in the
health facility. Patient’s information from RCH card or
medical registry was also used for addition information
and or clarifying issues.
Drug exposure and illness ascertainment
Participants were interviewed for any drug which was
taken prior to the enrolment but during the current
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given a small exercise book as patient’s medical log. The
latter was used whenever the woman went to the health
facility for treatment or to drug vender to fetch medica-
tion. Hence, all clinical information including drug used
was filled in this personal medical log. During each
monthly follow-up visit, participants were asked for any
new drug used, and in all cases evidence for the new
used medication was verified from prescription sheet,
RCH card, hospital registry or personal medical log.
However, in case of discordance between what had been
documented in RCH card or medical log and what the
participant had reported regarding the used medicine,
we relied on participant’s information after further inter-
view to verify specifications of the said medicine. Note
that use of a small exercise book as patient’s medical log
is routine practice in most of the dispensaries, health
centres, and some district hospitals in the country, may
be due to challenges of patients’ recordkeeping in most
health facilities. Hence, all patients are required by the
facility to have their own medical log whereby signs and
symptoms of illness, diagnostic findings, and prescrip-
tions are documented by health personnel. Patient’s
medical log is kept by the patient and he/she needs to
go with it to the health facility whenever seeking for
medical attention.
Gestational age and newborn assessment
The study recorded the following pregnancy informa-
tion: pregnancy outcomes (miscarriage, stillbirth or live
birth), mother’s complications at delivery, number of ba-
bies born, birth weight, gestational age at delivery (esti-
mated from the last date of normal menstrual period
[LNMP], or fundal height examination, when LNMP
was unknown), and any congenital abnormalities. In the
case of home delivery, women were advised to take the
baby to the hospital within seven days post-delivery for
proper examination.
Congenital abnormalities were assessed post-delivery
by a study clinician or health facility midwife. Screening
for congenital abnormalities was performed under the
guidance of a specifically developed checklist. The
screening was limited to identify external abnormalities
regardless the degree of severity. No examination was
performed to determine neurological scores for sensory
or motor patterns. Cases with suspected anomalies were
referred to the district and regional hospital for appro-
priate management.
Pregnancy risk of a drug exposure during pregnancy
period was categorized in accordance to US Food and
Drug Administration (FDA). US FDA classifies drugs
into five categories to describe their risk of teratogen-
icity; category A (adequate and well-controlled studies
have failed to demonstrate a risk to the fetus in alltrimesters), category B (animal reproductive studies have
failed to demonstrate a risk to the fetus and there are no
adequate and well-controlled studies in pregnant women),
category C (animal reproductive studies have shown an
adverse effect on the fetus and there are no adequate and
well-controlled studies in humans, but potential benefits
may warrant use of the drug in pregnant women despite
potential risks), category D (there is positive evidence of
human fetal risk based on adverse reaction data from in-
vestigational or marketing experience or studies in human,
but potential benefits may warrant use of the drug in
pregnant women despite potential risks), and category X
(studies in animals or humans have demonstrated fetal ab-
normalities and/or there is positive evidence of human
fetal risk based on adverse reaction data from investiga-
tional or marketing experience, and the risks involved in
use of the drug in pregnant women clearly outweigh po-
tential benefits) [20].
Sample size
The sample size was pre-determined by the size of
HDSS and the logistically feasible time frame of one
year. The number of women in their early pregnancy
which could be enrolled was estimated before (as 1000)
to be sufficient for pilot implementation of pharmacov-
igilance system in pregnancy but no formal sample size
calculation was performed.
Primary endpoints
The primary endpoint of the study was pregnancy out-
come. Pregnancy outcome included miscarriage, still-
birth or live birth, birth weight and prematurity status at
birth. Miscarriage was defined as loss of pregnancy be-
fore 28 weeks of gestation, and stillbirth was defined as
baby born with no signs of life at or after 28 weeks of
gestation. Low birth weight was defined as a birth weight
below 2500 g, and premature was defined as birth before
37 weeks of gestational age.
Statistical analysis
STATA® 12.0 (Stata Corporation, College Station, Texas,
USA) was used for data analysis. Numerical variables
were summarized into median and range. Categorical
variables were summarized using cross tabulation to es-
timate different proportion. Effects of maternal age,
weight and height, gestational age, parity, maternal
haemoglobin level, HIV and syphilis status on primary
endpoint of the study were assessed by bivariate analysis.
Logistic regression models were used to estimate the
crude odds ratio (OR) for the association between binary
pregnancy outcomes (birth outcome, birth weight and
birth maturity status) and medicines exposure. The multi-
variate adjusted logistic regression model included mater-
nal age and parity as potential confounding variables.
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the study endpoints, having a p value < 0.2 in bivariate
analysis, selection criteria to be included in the final
model. Two sided Wald test P-values are presented.
Ethics
Ethical approval for the study was granted by Ifakara
Health Institute (IHI) ethical review board and National
Institute for Medical Research (NIMR) ethical commit-
tee. Written informed consent was obtained from all
participants.
Results
A total of 1089 pregnant women were enrolled into the
study and 994 (91.3%) completed the follow-up. The lat-
ter constitutes the analysis population. 660 (66.4%) were
recruited from the health facility during their routine
RCH visits and 334 (33.6%) from the community
through house visit. Overall, 323 (32.5%) women were
recruited in first trimester of pregnancy with a mean
gestational age of 10.4 [standard deviation (SD) 2.3]
weeks and 671 (67.5%) in first half of second trimesterTable 1 Demographic and clinical characteristics of study wom
Characteristics First trimester
n = 323
Mean age, (years)* 26.4 (7.3; 14–49)
Mean BMI* 23.1 (3.8; 14.2-39.6)
Mean gestational age, (weeks)* 10.0 (2.2; 3–12)
Gravidity#
Primigravidae 82 (25.4)
Secundigravidae 62 (19.2)
3 – 4 pregnancies 99 (30.7)
≥ 5 pregnancies 80 (24.8)
Recruited sites#
Health facility 193 (59.8)
Home 130 (40.2)
Drinking alcohol# 3 (0.9)
Smoking cigarette# 2 (0.6)
Mean haemoglobin level, (g/dl)* 7.8 (4.7; 6.0-12.7)
HIV status#
Negative 284 (88.0)
Positive 12 (3.7)
No results 27 (8.3)
Syphilis test#
Negative 288 (89.2)
Positive 9 (2.8)
No results 26 (8.0)
*represents data presented in mean, (standard deviation [SD]; range).
#represents data presented in number (%).
Abbreviation: BMI Body Mass Index.of pregnancy with mean gestational age of 16.9 (SD 1.7)
weeks. Mean gestational age (SD) for participants re-
cruited in the community was 14.2 (4.1) weeks and 15.0
(3.2) for participants recruited in health facilities. Im-
portant demographic and clinical characteristics are
shown in Table 1.
Episodes of reported illnesses during pregnancy
Out of all enrolled pregnant women, 297 (29.9%) re-
ported to have at least one episode of illness during
pregnancy. Six diseases were reported: malaria 14.9%
(148), urinary tract infection (UTI) 9.2% (91), sexually
transmitted infections (STIs) 3.2% (32), upper respira-
tory tract infection (URTI) 1.5% (15), diarrhoea 1% (10)
and chickenpox 0.1% (1).
Drugs exposure during pregnancy
15 (1.5%) of all study participants reported not to have
used any drug during the pregnancy period. 974 (98%)
used any of the three drug groups that are recom-
mended by the Ministry of Health [21] for antenatal
intervention, all of which used during second and thirden at the time of enrollment (n = 994)
Second trimester Total
n = 671 n = 994
26.8 (7.0; 14–46) 26.6 (7.0; 14–49)
23.4 (3.4; 14.0-42.5) 23.3 (3.6; 14.0-42.5)
16.6 (1.9; 13–20) 14.8 (3.6; 3–20)
198 (29.5) 280 (28.2)
113 (16.8) 175 (17.6)
192 (28.6) 291 (29.3)
168 (25.1) 248 (24.9)
467 (69.6) 660 (66.4)
204 (30.4) 334 (33.6)
3 (0.4) 6 (0.6)
0 (0) 2 (0.2)
7.5 (4.6; 5.2-14.3) 7.7 (4.6; 5.2-14.3)
603 (89.9) 887 (89.2)
35 (5.2) 47 (4.7)
33 (4.9) 60 (6.0)
628 (93.6) 916 (92.2)
12 (1.8) 21 (2.1)
31 (4.6) 57 (5.7)
Table 3 RCH provided drugs and antimalarials exposure
in pregnant women (n = 994)
Drug group n (%)
SP for IPTp
Single dose 211 (21.2)
Two doses 735 (73.9)
Not at all 48 (4.8)
Anthelminthic (Mebendazole)
Yes 929 (93.5)
No 65 (6.5)
Iron and Folic acid supplementation
Yes 93 (93.7)
No 63 (6.3)
Patients treated for malaria at least once*
Yes 148 (14.9)
No 846 (85.1)
Types of antimalarials used in treating malaria
AL only 94 (9.5)
Quinine only 28 (2.8)
SP only 11 (1.1)
AL and Quinine 11 (1.1)
AL and SP 4 (0.4)
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supplements. 929 (93.5%) used anthelmintic (mebenda-
zole). 946 (95.2%) used at least one dose of sulfadoxine-
pyrimethamine (SP) for intermittent preventive treatment
of malaria (IPTp) [735 (73.9%) two doses and 211 (21.2%)
one dose] [see Tables 2 and 3].
For anti-infective drugs used because of illnesses, 170
(17.1%) women used antibiotics, 148 (14.9%) antimalarial
drugs, 59 (5.9%) antifungals and 29 (2.9%) antiretrovirals.
Some women used more than one type of either of the
mentioned anti-infective drugs during their pregnancy
period. Tables 2 and 3 summarize drugs exposures dur-
ing pregnancy among study women.
Based on United State Food and Drug Administration
(US FDA) risk categorization of drugs in pregnancy, the
most common drugs used under category ‘A’ were fer-
rous sulfate and folic acid, category ‘B’ paracetamol,
amoxicillin, erythromycin, metronidazole, benzathine
benzylpenicillin and ceftriaxone, category ‘C’ antimalar-
ial for treating illness (AL, quinine, SP), antiretroviral
(ARV) for HIV infection (zidovudine, lamivudine and
nevirapine), doxycycline, cotrimoxazole, aspirin, diclo-
phenac, hyoscine butylbromide and promethazine, cat-
egory ‘D’ traditional medicines and phenobarbitone,
and no category ‘X’.Table 2 Classes of drugs reported to be used by the
pregnant women
Class of drugs Number of women exposed (%)
Vitamins and minerals 931 (93.7)
Anthelminticsα 929 (93.5)
Analgesics 237 (23.8)
Antibiotics 170 (17.1)
Antimalarials α * 148 (14.9)
Antifungals 59 (5.9)
Antiretrovirals 29 (2.9)
Traditional medicine 27 (2.7)
Antihistamines 15 (1.5)
Antitussive 8 (0.8)
Antihypertensives 6 (0.6)
Antiasthmatics 5 (0.5)
Pregnancy risk categories#
A 931 (93.6)
B 253 (25.5)
C 233 (23.4)
D 46 (4.6)
X 0 (0.0)
αSee Table 3 for further details.
*Excluding SP for IPTp.
#Based on US FDA pregnancy risk categorization.
*Some women were treated for malaria more than one time during
pregnancy period.
Abbreviation: SP Sulfadoxine-pyrimethamine, IPPTp Intermittent Preventive
Treatment for malaria in pregnancy, AL Artemether-lumefantrine.Pregnancy outcome
Out of 994, 897 (90.2%) women delivered in health facil-
ities, 94 (9.5%) at home, and 3 (0.3%) along the road side
on their way to the health facility. There were three mater-
nal deaths which all occur within 24 hours post-delivery,
two of them due to post-partum haemorrhage and one sec-
ondary to eclampsia. Pregnancy outcomes included 28
(2.8%) abortions, 41 (4.1%) stillbirth and 925 (93.1%) live
births. Regarding birth outcomes, 99 (10.0%) were prema-
ture and 55 (5.0%) babies had low birth weight. 12 (1.2%) of
the newborns were identified as having congenital anomal-
ies at the time of birth: 8 were polydactyl and the remaining
4 had clubfoot, spina bifida, genital defect or cardiac defect.
Two women with a newborn having polydactyl each were
exposed to ARV and antitussive (coughing syrup), respect-
ively and both drugs are under US FDA risk category ‘C’.
One woman with a newborn having spina bifida was ex-
posed to phenobarbitone in third trimester, the drug which
is in US FDA risk category ‘D’. The remaining women with
congenital anomalies babies were not exposed to neither
US FDA category ‘C’ nor category ‘D’ drugs.
Relation of medication exposure to pregnancy outcome
Maternal age and parity were assessed to determine their
effect on pregnancy outcome (as potential confounders
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birth weight (0R 1.0; p value 0.356) but was associated
with 3% increased risk of premature birth (OR 1.03; p
value 0.038) and 4% increased risk of miscarriage/still-
birth (OR 1.04; p value 0.020). Parity had no significant
effect on miscarriage/stillbirth (OR 1.1; p value 0.690)
but was associated with a 60% increase risk of preterm
birth (OR 1.6; p value 0.065) and 60% decreased risk of
low birth weight (OR 0.6; p value 0.116).
With the level of risk assessment that this study was
powered, antimalarial exposure during pregnancy was
not significantly associated with an increased risk of
miscarriage/stillbirth (adjusted OR 1.3; 95%CI 0.7 -2.4;
p = 0.494), low birth weight (adjusted OR 0.7; 95CI%
0.3 – 1.8; p = 0.460) or premature birth (adjusted OR
1.2; 95%CI 0.6 – 2.7; p = 0.629). Antibiotics exposure was
neither associated with an increased risk of miscarriage/
stillbirth (adjusted OR 0.8; 95% CI 0.4 – 1.6; p = 0.526),
low birth weight (adjusted OR 0.6; 95% CI 0.2 – 1.6;Table 4 Antimalarial and antibiotics exposure in relation to p
Variables Outcomes
Birth outcome MC/SB Live birth
n (%) n (%)
Antimalarial exposure*
Yes 12 (17.4) 136 (14.7)
No 57 (82.6) 789 (85.3)
Antibiotics exposure
Yes 10 (14.5) 160 (17.3)
No 59 (85.5) 765 (82.7)
Birth weight (grams) < 2500 ≥ 2500
n (%) n (%)
Antimalarial exposure*
Yes 5 (11.4) 131 (14.9)
No 39 (88.6) 750 (85.1)
Antibiotics exposure
Yes 5 (11.4) 155 (17.6)
No 39 (88.6) 726 (82.4)
Maturity status at birth Preterm Term
n (%) n (%)
Antimalarial exposure*
Yes 8 (16.3) 128 (14.6)
No 41 (83.7) 748 (85.4)
Antibiotics exposure
Yes 11 (22.5) 149 (17.0)
No 38 (77.5) 727 (83.0)
MC/SB =Miscarriage or stillbirth; OR = odds ratio; CI = confidence interval.
*Excluding SP for IPTp.
μEstimated from the logistic regression model with Wald type P-value.
αAdjusted for parity and maternal age.p = 0.295) or premature birth (adjusted OR 1.4; 95%
CI 0.7 – 2.8; p = 0.348) [Table 4].
Exposure to drugs under US FDA pregnancy risk cat-
egory ‘A’, which mainly included ferrous sulfate and folic
acid were associated with a reduced risk of miscarriage/
stillbirth (adjusted OR 0.1; 95% CI 0.08 – 0.3; p < 0.001).
There was no significant association of adverse preg-
nancy outcome in relation to exposure to drugs under
category ‘B’, ‘C’ and ‘D’ [Table 5].
Discussion
The present study shows that there is a considerable
amount and several types of drugs exposure during
pregnancy in this region, as it may apply to other parts
of Tanzania and sub Saharan countries. To our know-
ledge, it is the first prospective study conducted in a
resource-limited setting that attempted to demonstrate
the feasibility of establishing a reliable pregnancy expos-
ure registry which followed a large group of pregnantregnancy outcome (n = 994)
Crude OR Pμ Adjusted ORα Pμ
(95% CI) (95% CI)
1.2 (0.6 – 2.3) 0.546 1.3 (0.7 – 2.4) 0.494
0.8 (0.4 – 1.6) 0.551 0.8 (0.4 – 1.6) 0.526
0.7 (0.3 – 1.9) 0.523 0.7 (0.3 – 1.8) 0.460
0.6 (0.2 – 1.5) 0.291 0.6 (0.2 – 1.6) 0.295
1.1 (0.5 – 2.5) 0.742 1.2 (0.6 – 2.7) 0.629
1.4 (0.7 – 2.8) 0.329 1.4 (0.7 – 2.8) 0.348
Table 5 US FDA pregnancy risk categories of drugs exposure in relation to pregnancy outcome
Variables Outcomes Crude OR Pμ Adjusted ORα Pμ
(95% CI) (95% CI)
Birth outcome MC/SB Live birth
n (%) n (%)
Drugs category ‘A’ 0.1 (0.1 – 0.3) < 0.001 0.1 (0.08 – 0.3) < 0.001
Yes 51 (73.9) 880 (95.1)
No 18 (26.1) 45 (4.9)
Drugs category ‘B’ 0.6 (0.3 – 1.1) 0.115 0.6 (0.3 – 1.1) 0.111
Yes 12 (17.4) 241 (26.1)
No 57 (82.6) 684 (73.9)
Drugs category ‘C’ 1.4 (0.8 – 2.3) 0.261 1.4 (0.8 – 2.4) 0.257
Yes 20 (29.0) 213 (23.0)
No 49 (71.0) 712 (77.0)
Drugs category ‘D’ 1.0 (0.3 – 2.9) 0.974 0.9 (0.3 – 3.2) 0.939
Yes 3 (4.3) 41 (4.4)
No 66 (95.7) 884 (95.6)
Birth weight (grams) < 2500 ≥ 2500
n (%) n (%)
Drugs category ‘A’ 0.5 (0.2 – 1.4) 0.191 0.5 (0.2 – 1.5) 0.207
Yes 40 (90.9) 840 (95.4)
No 4 (9.1) 41 (4.6)
Drugs category ‘B’ 0.5 (0.2 – 1.2) 0.122 0.5 (0.2 – 1.2) 0.125
Yes 7 (15.9) 234 (26.6)
No 37 (84.1) 647 (73.4)
Drugs category ‘C’ 0.7 (0.3 – 1.6) 0.436 0.7 (0.3 – 1.6) 0.387
Yes 8 (18.2) 205 (23.3)
No 36 (81.2) 676 (76.3)
Drugs category ‘D’ 0.5 (0.1 – 3.6) 0.485 0.6 (0.1 – 3.4) 0.449
Yes 1 (2.3) 40 (4.5)
No 43 (97.7) 841 (95.5)
Maturity status at birth Preterm Term
n (%) n (%)
Drugs category ‘A’ 0.6 (0.2 – 1.6) 0.277 0.5 (0.2 – 1.5) 0.231
Yes 45 (91.8) 835 (95.3)
No 4 (8.2) 41 (4.7)
Drugs category ‘B’ 1.5 (0.8 – 2.8) 0.160 1.5 (0.8 – 2.8) 0.175
Yes 17 (34.7) 224 (25.6)
No 32 (65.3) 652 (74.4)
Drugs category ‘C’ 1.4 (0.7 – 2.6) 0.345 1.4 (0.8 – 2.7) 0.269
Yes 14 (28.6) 199 (22.7)
No 35 (71.4) 677 (77.3)
Drugs category ‘D’ 2.0 (0.7 – 5.9) 0.201 2.0 (0.7 – 6.0) 0.200
Yes 4 (8.2) 37 (4.2)
No 45 (91.8) 839 (95.8)
MC/SB =Miscarriage or stillbirth; OR = odds ratio; CI = confidence interval.
μEstimated from the logistic regression model with Wald type P-value.
αAdjusted for parity and maternal age.
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exposure and related diseases during pregnancy period
were carefully identified and recorded.
More than 98% of study women reported to have used
at least one medication during pregnancy. This is more
than twice to what was observed in Mozambique in a
study conducted seven years ago [8]. Most of the drugs
used were the ones covered under antenatal intervention
program. The coverage of anthelmintic, haematemic and
SP for IPTp in our study was almost twice that esti-
mated at national level [23]. This high use of drugs may
be the result of intense health promotion activities in
the area under HDSS, in close collaboration with local
and government authorities. A 94% coverage for iron
and folic acid supplementations in this rural area is a re-
markable achievement. Apart from haematemic, anthel-
minthic and IPTp-SP exposure, analgesics were the most
reported prescribed drugs. This observation is in agree-
ment with two previous studies in sub-Saharan Africa
[8,24]. Over- or under- reporting of drug use is of course
possible due to recall bias, particularly for women en-
rolled in an advanced gestational age and with poor
documentation of the medicine used. Errors on gesta-
tional age measurement cannot be excluded as well.
Malaria was the most often recorded illness during
pregnancy (15%). This illustrates the high intensity of
transmission in the study area [16] and the vulnerability
of pregnant women to malaria [25]. It highlights the im-
portance of having safe and effective drugs to clear para-
sites during pregnancy. AL was prescribed nearly 3
times more often than quinine. Some of these treat-
ments correspond to inadvertent exposure, similarly to
what has been observed in Sudan and Zambia [26,27].
Others represent treatments that were probably adminis-
tered during second and third trimester, as recom-
mended [12]. A better availability of AL when compared
to quinine in health facilities and drug shops [2] may
have also contributed to the frequent use of this drug.
When taken as a category and irrespective of the tim-
ing during pregnancy, antimalarial and antibiotic expo-
sures were not associated with adverse pregnancy
outcome. This result should be interpreted with caution
since different types of medications, or the same medica-
tion but given at different time during pregnancy, may
have different effects. A more detailed assessment of
antimalarial exposure, taking into account the type and
time of exposure during pregnancy have been reported
elsewhere in a complementary study which included a
larger sample size of pregnant women from two HDSS
areas [14]. The present paper was more to pilot the
feasibility of a pharmacovigilance system embedded in a
HDSS in a developing country.
Iron and folic acid supplementation, the main drugs
under US FDA pregnancy risk category ‘A’ were protectiveagainst miscarriage/stillbirth. However, adherence to these
supplements and number of doses prescribed were not
assessed. There was no much evidence yet to support the
added benefits of these supplements in preventing miscar-
riage or stillbirth. Evidence mainly supports the use of
these drugs to prevent anaemia and iron deficiency at
term, to reduce the risk of low birth weight and early neo-
natal death, all factors that have shown to have a beneficial
impact on child’s survival [28-30]. The observed beneficial
effects of recommended iron and folic acid supplementa-
tion in pregnancy validate the concept of pharmacovigi-
lance system through HDSS.
About 3% of study women used traditional medicines
which in most cases are under pregnancy risk category
‘D’. The use of traditional medicines may have been
higher than what is reported in the present study since
participants were interviewed by health care providers
who are trained to discourage patients to use herbs.
Underreporting is a well-known phenomenon in other
developing countries whereby study participants had dif-
ficulties to disclose use of traditional medicine to the
health care professionals [8,31].
The observed prevalence of 1.2% congenital anomalies
in the study is lower compared to the 3.0% global preva-
lence estimated by the WHO [32]. There is no national
register to compare our rate with that in other parts of
the country. The observed rate of congenital anomalies
in the present study may be underestimated because
screening for anomalies was limited to the external ones
and was carried out only once, at the time of delivery.
Hence, there are possibilities of more anomalies to be
identified later in life as the child grows. It would be im-
portant to follow all delivered babies prospectively at de-
fined intervals, at least until the age of one year to
monitor sensory and motor developmental milestones.
Such a monitoring can be easily implemented in HDSS
settings. In addition, it is also important to consider im-
proving newborn’s screening standards, training of health
staff and detailed birth registry records to implement a re-
liable pregnancy pharmacovigilance system [22].
The present study demonstrates a way forward to es-
tablish a feasible, reliable and manageable active phar-
macovigilance system in a resource-limited setting by
taking advantage of existing monitoring platforms such
as HDSS. Pregnancy pharmacovigilance system under
HDSS platform may be cost-effective due to the already
existing infrastructure such as personnel and established
database constantly updated. Feasibility of the present
proposed pharmacovigilance system is of merit over the
probabilistic record linkage for monitoring antimalarial
safety evaluated in Senegal [7] which is subjected to bias
because of poor medical record system in most health
facilities in developing countries and hence, some expos-
ure cases and pregnancy outcome information may
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proposed by Mehta U et al. [22] appears to be promising
but its operational costs may be very high in most
resource-limited countries where presence of skilled
medical personnel is still a big problem.
Pharmacovigilance systems should reduce the uncer-
tainty about safety of newly marketed medication against
tropical diseases. Such a system that collects systematic-
ally reliably data to determine whether a given medica-
tion is teratogenic or not through monitoring of a large
exposure group could provide strong evidence on safety
[13,22]. It could help to overcome the current shortfall
which is commonly seen in medical practice when treat-
ing a pregnant woman with medication that has subopti-
mal efficacy because of potential safety problems. Also,
it could assist in the assessment of medicines that are
not recommended during pregnancy, but are sometimes
not avoidable to save the mother or the unborn child.Conclusion
Almost all women are exposed to medication during
pregnancy, either because drugs are recommended dur-
ing this period, or because women are sick and need
treatment. Since exposure to contraindicated drugs dur-
ing pregnancy is sometimes inevitable in either trimester,
safety monitoring mechanism should be in place in
order to generate reliable information for the promotion
of safe and effective treatment during pregnancy. HDSS
sites can have a useful role in providing reliable pharma-
covigilance data and the experience from its success will
be helpful to expand the system to none HDSS areas.
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